Literature DB >> 22009379

Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Mateen C Moghbel, Babak Saboury, Sandip Basu, Scott D Metzler, Drew A Torigian, Bengt Långström, Abass Alavi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22009379     DOI： 10.1007/s00259-011-1960-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  55 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

3.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

4.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 5.  Alzheimer's vaccine: a cure as dangerous as the disease?

Authors:  G Münch; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2002-04       Impact factor: 3.575

6.  Cerebral amyloid angiopathy in dementia and old age.

Authors:  M M Esiri; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

Review 7.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years.

Authors:  Najeeb A Ranginwala; Linda S Hynan; Myron F Weiner; Charles L White
Journal:  Am J Geriatr Psychiatry       Date:  2008-05       Impact factor: 4.105

10.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205
View more
  6 in total

Review 1.  Amyloid-β positron emission tomography imaging probes: a critical review.

Authors:  Vladimir Kepe; Mateen C Moghbel; Bengt Långström; Habib Zaidi; Harry V Vinters; Sung-Cheng Huang; Nagichettiar Satyamurthy; Doris Doudet; Eyal Mishani; Robert M Cohen; Poul F Høilund-Carlsen; Abass Alavi; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  Neuronuclear imaging in the evaluation of dementia and mild decline in cognition.

Authors:  Nare Torosyan; Daniel H S Silverman
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

3.  Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach.

Authors:  Abass Alavi; Jorge R Barrio; Thomas J Werner; Mohsen Khosravi; Andrew Newberg; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02       Impact factor: 9.236

4.  Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain.

Authors:  Gurleen K Samra; Kenneth Dang; Heather Ho; Aparna Baranwal; Jogeshwar Mukherjee
Journal:  Med Chem Res       Date:  2018-04-07       Impact factor: 1.965

Review 5.  Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

Authors:  Chetsadaporn Promteangtrong; Marcus Kolber; Priya Ramchandra; Mateen Moghbel; Sina Houshmand; Michael Schöll; Thomas J Werner; Abass Alavi; Carlos Buchpiguel
Journal:  Dement Neuropsychol       Date:  2015 Oct-Dec

6.  A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.

Authors:  Anders Wimo; Mark Belger; Jaka Bon; Frank Jessen; Annette Dumas; Milica G Kramberger; Laura Jamilis; Gunilla Johansson; Adrián Rodrigo Salas; Octavio Rodríguez Gómez; Lena Sannemann; Malou Stoekenbroek; Miren Gurruchaga Telleria; Sergi Valero; Lisa Vermunt; Lisa Waterink; Bengt Winblad; Peter Jelle Visser; Marissa Zwan; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.